These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32060897)

  • 21. Treating osteoporosis to prevent fractures: current concepts and future developments.
    Lorentzon M
    J Intern Med; 2019 Apr; 285(4):381-394. PubMed ID: 30657216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which Drug Next? Sequential Therapy for Osteoporosis.
    Lukert BP
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31922566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
    Horne AM; Mihov B; Reid IR
    Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates for delivering drugs to bone.
    Sun S; Tao J; Sedghizadeh PP; Cherian P; Junka AF; Sodagar E; Xing L; Boeckman RK; Srinivasan V; Yao Z; Boyce BF; Lipe B; Neighbors JD; Russell RGG; McKenna CE; Ebetino FH
    Br J Pharmacol; 2021 May; 178(9):2008-2025. PubMed ID: 32876338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2011 Jul; 69(7):1253-7. PubMed ID: 21774367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Osteoporosis].
    Biver E; Ferrari S
    Rev Med Suisse; 2020 Jan; 16(676-7):78-80. PubMed ID: 31961090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention of osteoporotic fracture by pharmaceutical interventions].
    Nakamura T
    Clin Calcium; 2006 Dec; 16(12):1961-67. PubMed ID: 17142925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.
    Melek J; Sakuraba A
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):32-44.e5. PubMed ID: 23981521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoporosis assessment and treatment in older patients who have sustained a hip fracture.
    Lowdon DW; Quinn C; Mole P; Leese GP
    Scott Med J; 2006 May; 51(2):32-5. PubMed ID: 16722136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
    Boonen S; Ferrari S; Miller PD; Eriksen EF; Sambrook PN; Compston J; Reid IR; Vanderschueren D; Cosman F
    J Bone Miner Res; 2012 May; 27(5):963-74. PubMed ID: 22467094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
    Berry SD; Dufour AB; Travison TG; Zhu H; Yehoshua A; Barron R; Recknor C; Samelson EJ
    Arch Osteoporos; 2018 Nov; 13(1):124. PubMed ID: 30421141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
    Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
    Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.